Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Stock Rated “Hold” by Sell-Side Analysts

Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) have been assigned an average recommendation of “Hold” from the thirteen analysts that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and two have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $21.85.

Several research analysts have recently weighed in on the stock. Wall Street Zen raised shares of Eyepoint Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday, September 27th. Chardan Capital cut shares of Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $5.00 target price on the stock. in a report on Tuesday, August 18th. HC Wainwright reaffirmed a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, October 20th. Weiss Ratings raised shares of Eyepoint Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 1st. Finally, Mizuho lowered shares of Eyepoint Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $0.50 target price for the company. in a research note on Tuesday, October 20th.

Eyepoint Pharmaceuticals Stock Down 8.3%

Shares of NASDAQ EYPT opened at $0.35 on Friday. Eyepoint Pharmaceuticals has a twelve month low of $0.34 and a twelve month high of $19.11. The company has a 50 day moving average of $3.21 and a 200 day moving average of $11.01. The firm has a market cap of $30.04 million, a P/E ratio of -0.09 and a beta of 1.67.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The business had revenue of $0.51 million for the quarter, compared to the consensus estimate of $0.45 million. As a group, equities analysts expect that Eyepoint Pharmaceuticals will post -3.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

A number of large investors have recently made changes to their positions in EYPT. Janus Henderson Group PLC raised its stake in Eyepoint Pharmaceuticals by 22.6% during the 1st quarter. Janus Henderson Group PLC now owns 3,601,168 shares of the company’s stock valued at $46,419,000 after purchasing an additional 663,439 shares during the period. Commodore Capital LP purchased a new stake in Eyepoint Pharmaceuticals during the 1st quarter valued at approximately $36,414,000. Hsbc Holdings PLC bought a new stake in shares of Eyepoint Pharmaceuticals during the first quarter valued at approximately $10,743,000. Stempoint Capital LP grew its stake in Eyepoint Pharmaceuticals by 129.1% during the first quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock valued at $10,451,000 after acquiring an additional 456,915 shares in the last quarter. Finally, Principia Wealth Advisory LLC grew its stake in Eyepoint Pharmaceuticals by 2.6% during the second quarter. Principia Wealth Advisory LLC now owns 649,944 shares of the company’s stock valued at $9,294,000 after acquiring an additional 16,180 shares in the last quarter. 99.41% of the stock is currently owned by institutional investors.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for serious eye diseases. The company specializes in sustained-release drug delivery for the retina and other parts of the eye, with the goal of reducing the frequency of injections and improving treatment convenience for patients.

EyePoint’s commercial products include YUTIQ, an injectable fluocinolone acetonide intravitreal implant used to treat chronic noninfectious posterior uveitis, and DEXYCU, an ophthalmic formulation of dexamethasone used to treat inflammation following ocular surgery.